Increasing scientific knowledge and technical innovations in the areas of cell biology, biotechnology and medicine resulted in the development of promising therapeutic approaches for the prevention and treatment of human diseases. Advanced therapy medicinal products (ATMPs) reflect a complex and innovative class of bio-pharmaceuticals as these products are highly research-driven, characterised by innovative manufacturing processes and heterogeneous with regard to their origin, type and complexity. This class of ATMP integrates gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineering products and are often individualized and patient-specific products. Multiple challenges arise from the nature of ATMPs, which are often developed by micro, small and medium sized enterprises, university and academia, for whom regulatory experiences are limited and regulatory requirements are challenging. Regulatory guidance such as the reflection paper on classification of ATMPs and guidelines highlighting product-specific issues support academic research groups and pharmaceutical companies to foster the development of safe and effective ATMPs. This review provides an overview on the European regulatory aspects of ATMPs and highlights specific regulatory tools such as the ATMP classification procedure, a discussion on the hospital exemption for selected ATMPs as well as borderline issues towards transplants/transfusion products.

1.
Committee for Advanced Therapies (CAT); CAT Scientific Secretariat, Schneider CK, Salmikangas P, Jilma B, Flamion B, Todorova LR, Paphitou A, Haunerova I, Maimets T, Trouvin JH, Flory E, Tsiftsoglou A, Sarkadi B, Gudmundsson K, O'Donovan M, Migliaccio G, Ancāns J, Maciulaitis R, Robert JL, Samuel A, Ovelgönne JH, Hystad M, Fal AM, Lima BS, Moraru AS, Turcáni P, Zorec R, Ruiz S, Akerblom L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D, Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou M, Pychova A, Clausen M, Methuen T, Lucas S, Schüssler-Lenz M, Kokkas V, Buzás Z, MacAleenan N, Galli MC, Linē A, Gulbinovic J, Berchem G, Fraczek M, Menezes-Ferreira M, Vilceanu N, Hrubisko M, Marinko P, Timón M, Cheng W, Crosbie GA, Meade N, di Paola ML, VandenDriessche T, Ljungman P, D'Apote L, Oliver-Diaz O, Büttel I, Celis P: Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 2010;9:195-201.
2.
Salmikangas P, Flory E, Reinhardt J, Hinz T, Maciulaitis R: Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products (in German). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2010;53:24-29.
3.
Reinhardt J, Flory E, Büttel I, Schröder C, Fricke S, Vucinic V, Cross M, Niederwieser D: MSCs: clinical applications and European regulatory aspects; in Hematti P, Keating A (eds): Mesenchymal Stromal Cells. Biology and Clinical Applications. New York, Springer, 2013, pp 355-364.
4.
Regulation (EC) 1394/2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation No 726/2004.
5.
Sanzenbacher R, Dwenger A, Schuessler-Lenz M, Cichutek K, Flory E: European regulation tackles tissue-engineering. Nat Biotechnol 2007;25:1089-1091.
6.
EMA: Reflection Paper on Classification of Advanced Therapy Medicinal Products. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/12/WC500136422.pdf.
7.
Berger A, Schule S, Flory E: The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises (in German). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2011;54:816-821.
8.
Directive 2004/23/EC of the European Parliament and of the Council (31 March 2004) on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri = OJ:L:2004:102:0048:0058:EN:PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.